AU2014231229A1 - Single high dose of MVA induces a protective immune response in neonates and infants - Google Patents

Single high dose of MVA induces a protective immune response in neonates and infants Download PDF

Info

Publication number
AU2014231229A1
AU2014231229A1 AU2014231229A AU2014231229A AU2014231229A1 AU 2014231229 A1 AU2014231229 A1 AU 2014231229A1 AU 2014231229 A AU2014231229 A AU 2014231229A AU 2014231229 A AU2014231229 A AU 2014231229A AU 2014231229 A1 AU2014231229 A1 AU 2014231229A1
Authority
AU
Australia
Prior art keywords
mva
administration
tcid
human
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014231229A
Other languages
English (en)
Inventor
Paul Chaplin
Cedric Cheminay
Mark Suter
Ariane Volkmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of AU2014231229A1 publication Critical patent/AU2014231229A1/en
Priority to AU2019200977A priority Critical patent/AU2019200977A1/en
Priority to AU2020260472A priority patent/AU2020260472A1/en
Priority to AU2022235527A priority patent/AU2022235527B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AU2014231229A 2013-03-15 2014-03-14 Single high dose of MVA induces a protective immune response in neonates and infants Abandoned AU2014231229A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2019200977A AU2019200977A1 (en) 2013-03-15 2019-02-12 Single high dose of mva induces a protective immune response in neonates and infants
AU2020260472A AU2020260472A1 (en) 2013-03-15 2020-10-29 Single high dose of mva induces a protective immune response in neonates and infants
AU2022235527A AU2022235527B2 (en) 2013-03-15 2022-09-20 Single high dose of mva induces a protective immune response in neonates and infants

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361788722P 2013-03-15 2013-03-15
US61/788,722 2013-03-15
PCT/EP2014/000693 WO2014139687A1 (en) 2013-03-15 2014-03-14 Single high dose of mva induces a protective immune response in neonates and infants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200977A Division AU2019200977A1 (en) 2013-03-15 2019-02-12 Single high dose of mva induces a protective immune response in neonates and infants

Publications (1)

Publication Number Publication Date
AU2014231229A1 true AU2014231229A1 (en) 2015-09-17

Family

ID=50389388

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2014231229A Abandoned AU2014231229A1 (en) 2013-03-15 2014-03-14 Single high dose of MVA induces a protective immune response in neonates and infants
AU2019200977A Abandoned AU2019200977A1 (en) 2013-03-15 2019-02-12 Single high dose of mva induces a protective immune response in neonates and infants
AU2020260472A Abandoned AU2020260472A1 (en) 2013-03-15 2020-10-29 Single high dose of mva induces a protective immune response in neonates and infants
AU2022235527A Active AU2022235527B2 (en) 2013-03-15 2022-09-20 Single high dose of mva induces a protective immune response in neonates and infants

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2019200977A Abandoned AU2019200977A1 (en) 2013-03-15 2019-02-12 Single high dose of mva induces a protective immune response in neonates and infants
AU2020260472A Abandoned AU2020260472A1 (en) 2013-03-15 2020-10-29 Single high dose of mva induces a protective immune response in neonates and infants
AU2022235527A Active AU2022235527B2 (en) 2013-03-15 2022-09-20 Single high dose of mva induces a protective immune response in neonates and infants

Country Status (17)

Country Link
US (1) US9707291B2 (cg-RX-API-DMAC7.html)
EP (2) EP2968524A1 (cg-RX-API-DMAC7.html)
JP (1) JP6480875B2 (cg-RX-API-DMAC7.html)
KR (1) KR102269491B1 (cg-RX-API-DMAC7.html)
CN (1) CN105101993A (cg-RX-API-DMAC7.html)
AU (4) AU2014231229A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015021781A2 (cg-RX-API-DMAC7.html)
CA (1) CA2905569C (cg-RX-API-DMAC7.html)
EA (1) EA034825B1 (cg-RX-API-DMAC7.html)
HK (1) HK1216860A1 (cg-RX-API-DMAC7.html)
IL (1) IL241059B (cg-RX-API-DMAC7.html)
MX (1) MX376293B (cg-RX-API-DMAC7.html)
MY (1) MY175269A (cg-RX-API-DMAC7.html)
SG (2) SG10201707340XA (cg-RX-API-DMAC7.html)
UA (1) UA126785C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014139687A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201507017B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034825B1 (ru) * 2013-03-15 2020-03-25 Бавариан Нордик А/С Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев
WO2015136056A1 (en) 2014-03-12 2015-09-17 Bavarian Nordic A/S Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
US20230233670A1 (en) * 2020-06-10 2023-07-27 Bavarian Nordic A/S A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9117596D0 (en) * 1991-08-15 1991-10-02 John Gibson Lifting Gear Ltd Pulling system
US5471902A (en) * 1994-02-22 1995-12-05 Athenry Enterprises Limited Tuning system for pianos
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
HU230198B1 (hu) * 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
EP1420822B2 (en) 2002-04-19 2017-07-05 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
CN101128217B (zh) * 2005-02-23 2012-04-25 巴法里安诺迪克有限公司 改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途
CA2662730A1 (en) * 2006-09-08 2008-03-13 Bavarian Nordic A/S Phenotypic and genotypic differences of mva strains
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
JP2013507107A (ja) * 2009-10-08 2013-03-04 バヴァリアン・ノルディック・アクティーゼルスカブ Hivに対するヒトにおける広範なt細胞応答の生成
US9463238B2 (en) * 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
US10111946B2 (en) * 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
SI2879702T1 (sl) * 2012-08-01 2020-02-28 Bavarian Nordic A/S Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV)
EA034825B1 (ru) * 2013-03-15 2020-03-25 Бавариан Нордик А/С Разовые высокие дозы mva индуцируют защитный иммунный ответ у новорожденных и младенцев

Also Published As

Publication number Publication date
MX2015011388A (es) 2016-02-03
EP3708187A1 (en) 2020-09-16
JP6480875B2 (ja) 2019-03-13
NZ711569A (en) 2021-03-26
AU2020260472A1 (en) 2020-11-26
IL241059A0 (en) 2015-11-30
ZA201507017B (en) 2018-12-19
IL241059B (en) 2020-10-29
JP2016514114A (ja) 2016-05-19
BR112015021781A2 (pt) 2017-07-18
HK1216860A1 (zh) 2016-12-09
SG11201507192SA (en) 2015-10-29
US9707291B2 (en) 2017-07-18
AU2019200977A1 (en) 2019-02-28
EA201591803A1 (ru) 2016-02-29
UA126785C2 (uk) 2023-02-08
AU2022235527B2 (en) 2023-10-26
CN105101993A (zh) 2015-11-25
CA2905569A1 (en) 2014-09-18
KR20150129027A (ko) 2015-11-18
SG10201707340XA (en) 2017-10-30
MY175269A (en) 2020-06-17
KR102269491B1 (ko) 2021-06-25
US20160030551A1 (en) 2016-02-04
EP2968524A1 (en) 2016-01-20
EA034825B1 (ru) 2020-03-25
AU2022235527A1 (en) 2022-10-13
WO2014139687A1 (en) 2014-09-18
CA2905569C (en) 2023-07-25
MX376293B (es) 2025-03-07

Similar Documents

Publication Publication Date Title
AU2022235527B2 (en) Single high dose of mva induces a protective immune response in neonates and infants
AU2003239805B2 (en) Modified vaccinia virus ankara for the vaccination of neonates
AU2004276486B2 (en) Modified vaccinia virus ankara (MVA) mutant and use thereof
US8535687B2 (en) Smallpox DNA vaccine and the antigens therein that elicit an immune response
CN107454848B (zh) 用于诱导针对丝状病毒感染的保护性免疫的方法和组合物
CA2676809C (en) Immediate protection against pathogens via mva
EP3116541B1 (en) Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus
Cheminay et al. A single vaccination with non-replicating MVA at birth induces both immediate and long-term protective immune responses
NZ711569B2 (en) Single high dose of mva induces a protective immune response in neonates and infants
Bissa et al. Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted